Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Drug Delivery Products
Cannasat Therapeutics Inc. and IntelGenx Corp. announced a long-term collaborative agreement to co-develop novel cannabinoid-based products through a combination of Cannasat's and IntelGenx's proprietary drug delivery technologies. The collaboration will focus on the development and production of new formulations of cannabinoid pharmaceutical products, starting with Cannasat's lead product, CAT 310.
"We are excited to work with IntelGenx to develop new cannabinoid pharmaceuticals that could potentially address a wide range of therapeutic indications such as neuropathic pain, where there is currently a large unmet medical need for new therapies. IntelGenx's technology platform complements our existing drug delivery technologies and provides us an opportunity to broaden our growing intellectual property portfolio and product development pipeline. We are committed to expanding our arsenal of drug delivery technologies that can enhance the effectiveness of cannabinoid-based drugs," said David Hill, CEO of Cannasat Therapeutics.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.